Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 30;11:9381. doi: 10.1038/s41598-021-89043-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Disease course and treatment timeline for patients with type 1 and type 2 pleural effusions. Red Arrow: Pleural effusion requiring thoracentesis. Time line highlighted in yellow: progression free survival (the number within the timeline indicates the month after the immune checkpoint inhibitor (ICI) initiation). The left side of the yellow bar refers to the initiation of the ICI. The regimens of each patient were listed above the timeline. Ci, cisplatin; A, pemetrexed (Alimta); D, docetaxel; P, paclitaxel; E, etoposide; G, gemcitabine; V, vinorelbine; Pembro, pembrolizumb; OP, surgical intervention; TKI, EGFR-tyrosine kinase inhibitor; B, bevacizumab; Ce, cetuximab; Ca, carboplatin; Durva, durvalumab; Nivo, nivolumab; I, irinotecan.